Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-phenylbutyrate to prevent glucocorticoid-induced intraocular pressure increase
2015-000225-36Phase 2Terminated
- Sponsor
- Helsinki University Hospital
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of sodium phenylbutyrate in ocular hypertension (3 arms), sponsored by Helsinki University Hospital. Primary endpoints: Prevention of intraocular pressure increase (groups 1 and 3) and Decrease in intraocular pressure (group 2). Started Jan 2015; status: terminated.
02
Drugs
sodium phenylbutyrate
03
Conditions
ocular hypertension
Beyond the preview
Go deeper on 2015-000225-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000225-36.